Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Inventiva ( (IVA) ).
On November 6, 2025, Inventiva announced the availability of preparatory documents for their Combined General Meeting scheduled for November 27, 2025. This meeting will address the approval of compensation policies for the newly appointed CEO, Andrew Obenshain, and the departure terms for the former CEO, Frédéric Cren, whose term ended on September 30, 2025. The meeting will also authorize the board to modify certain share plans for Mr. Cren in recognition of his contributions. This transition aims to ensure continuity in Inventiva’s strategic priorities and operations.
The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative margins. The technical analysis further indicates a bearish trend, while the valuation metrics highlight ongoing financial challenges. The absence of earnings call data and corporate events does not influence the score.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for treating metabolic dysfunction-associated steatohepatitis (MASH). The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for MASH treatment. Inventiva is publicly listed on Euronext Paris and the Nasdaq Global Market.
Average Trading Volume: 159,852
Technical Sentiment Signal: Buy
Current Market Cap: $616.8M
For a thorough assessment of IVA stock, go to TipRanks’ Stock Analysis page.